BiotechTube

Valbenazine + Placebo oral capsule

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Tardive Dyskinesia (TD)

Conditions

Tardive Dyskinesia (TD)

Trial Timeline

Sep 14, 2018 → Apr 3, 2019

NCT ID
NCT03698331

About Valbenazine + Placebo oral capsule

Valbenazine + Placebo oral capsule is a approved stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia (TD). The current trial status is completed. This product is registered under clinical trial identifier NCT03698331. Target conditions include Tardive Dyskinesia (TD).

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (4)

NCT IDPhaseStatus
NCT03891862ApprovedCompleted
NCT03698331ApprovedCompleted
NCT03530293Phase 2Terminated
NCT03325010Phase 2Completed

Competing Products

13 competing products in Tardive Dyskinesia (TD)

See all competitors
ProductCompanyStageHype Score
SarizotanMerckPre-clinical
23
levetiracetam + placeboUCBPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 1
30
Valbenazine Oral CapsuleNeurocrine BiosciencesApproved
82
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 3
74
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-98854Neurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 3
74
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-1065890 + PlaceboNeurocrine BiosciencesPhase 2
49

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
NBI-1117568Phase 3
74